Odanacatib (MK 0822) is an inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K (IC50=0.2nM), which may result in a reduction in bone resorption, improvement of bone mineral density, and a reversal in osteoporotic changes. Odanacatib is currently in clinical development for the treatment of postmenopausal osteoporosis
ChemScene can order timely high quality and efficient services of various compounds from mg to kg level for some clients' bioscience research. We are committed to researching and developing reference compounds with high synthesis technology barriers and difficulties. ChemScene also has a tradition of working with scientists to bring new discoveries out of the laboratory and into the commercial arena.
View more >>